DLDorien Laenens

Dorien Laenens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dorien Laenens has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ST-segment elevation myocardial infarction in older adults: echocardiographic characterization and outcomes in contemporary practice

    by Laima Caunite, Rinchyenkhand Myagmardorj, Xavier Galloo, Dorien Laenens, Jan Stassen, Takeru Nabeta, Idit Yedidya, Maria Chiara Meucci, Jurrien H. Kuneman, Inge J. van Den Hoogen, et al.

    Evidence on cardiac remodeling, left ventricular (LV) function recovery, medication use and outcomes in older ST-segment elevation myocardial infarction (STEMI) patients is limited. We examined these aspects at baseline and evolution one year post-infarct in patients aged ≥ 80 versus < 80.STEMI registry data were retrospectively analyzed. The older subgroup included patients aged ≥ 80 years at index hospitalization. Echocardiography was performed at baseline and one year after STEMI. LV remodeling was defined as > 20% relative increase in the LV end-diastolic volume. One-year cardiovascular outcomes and five-year all-cause mortality are reported.Study included 2178 patients; 132 (6.1%) were aged ≥ 80. Older patients had worse baseline LV ejection fraction (47.2 ± 9.6% versus 49.8 ± 8.2%; p < 0.001) and experienced more adverse LV remodeling (29% versus 19%; p = 0.024). Nevertheless, LV function improved similarly in both groups. Beta-blocker and renin-angiotensin-aldosterone system inhibitor use was lower (86.4% versus 94.2%; p < 0.001 and 90.2% versus 96.5%; p < 0.001, respectively) but diuretic prescription higher (18.2% versus 8.1%; p < 0.001) in older patients. One year post-infarct beta-blocker and renin-angiotensin-aldosterone system inhibitor use decreased and was similar in both groups, but older patients continued to receive more diuretics and suffered higher heart failure hospitalization rates (7.0% versus 2.6%; p = 0.006). Five-year mortality was 25.8% in older versus 4.3% in younger patients (log-rank χ2 133.2; p < 0.001).Older patients experienced more adverse LV remodeling, received less beta-blockers and renin-angiotensin-aldosterone system inhibitors but more diuretics at discharge and one year, compared to younger patients. Nevertheless, LV function recovered similarly in both groups.


  • Open Access

    Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study

    by Dorien Laenens, Philippe Debonnaire, Maarten A J De Smet, Fausto Pinto, Dulce Brito, Steven Droogmans, Frederik H Verbrugge, Erwan Donal, Nico Van de Veire, Philippe Bertrand, et al.

    Introduction: Data on the impact of a heart failure hospitalization (HFH) on outcome in patients with transthyretin cardiac amyloidosis (TTR-CA) are scarce, although it remains a frequent adverse event. To assess the characteristics of patients with HFH in a real-world TTR-CA population, the occurrence of HFH, and the prognosis thereafter. Methods: Data were collected from a multicentre TTR-CA registry and patients were dichotomized according to the occurrence of at least one HFH. Landmark analysis at the 1-year follow-up and Cox regression analysis with HFH as a time-dependent covariate were performed to assess the impact of HFH on all-cause mortality. Results: Overall, 654 patients were included [median age 78 (64, 83) years, 70.5% male, 70.6% wild type]. During a median follow-up of 24 (11–45) months, 141 (22%) patients experienced at least one HFH and 170 (26%) patients died. Patients with a HFH were older (82 vs 76 years, P < .001), had more wild-type TTR-CA [126 (89.4%) vs 336 (65.5%), P < .001], were more symptomatic [New York Heart Association Class II–IV 119 (86.9%) vs 279 (62%), P < .001], had higher National Amyloidosis Centre (NAC) disease stage, were less treated with disease-modifying therapy [45 (31.9%) vs 247 (47.4%), P = .001], had more co-morbidities and showed signs of more advanced disease by echocardiography. At the 1-year time point, patients with HFH had significant worse overall survival (log-rank χ² 37.673, P < .001). At the univariable (HR 7.71, 95%CI 5.50, 10.82; P < .001) and multivariable analyses, HFH was associated with all-cause mortality and showed incremental value on top of clinical variables, biomarkers [estimated glomerular filtration rate in Model 1 (χ² 97.3; P < .001) and NAC disease stage in Model 2 (χ² 78.8; P < .001)] and echocardiographic parameters (left ventricular mass index + stroke volume index + significant valvular lesion in Model 3 (χ² 60.3; P < .001) and including E/e′ in Model 4 (χ² 43.4; P < .001)). Conclusion: HFH is independently associated with all-cause mortality in patients with TTR-CA and has incremental value on top of established risk models.

  • Open Access

    Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort

    by Eva H. van der Geest, Nina Ajmone Marsan, Dorien Laenens, Philippe J. M. R. Debonnaire, Mathias Claeys, Fauto Pinto, Dulce Brito, Erwan Donal, Steven Droogmans, Nico Van de Veire, et al.

    Background: Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort. Methods: A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divided based on guideline publication dates. Results: Patients were predominantly male (73.2%) with a median age of 78 years. Prescription of diuretics (52.8%) and disease-modifying therapy (44.9%), mostly tafamidis, was common. BBs (43.7%) and ACEi/ARBs (41.2%) were prescribed more often in patients with higher NYHA class, elevated NT-proBNP, and more comorbidities. Blood pressure and heart rate were similar regardless of BB or ACEi/ARB use. BB prescription and combination therapy with BB and ACEi/ARB increased over time. Neither BB nor ACEi/ARB use significantly impacted mortality when analyzed in a multivariate Cox proportional hazard regression. Conclusions: Use of BBs and ACEi/ARBs has increased over time, particularly in advanced-stage ATTR-CA patients, and although these therapies appear to be reasonably tolerated, survival was not significantly altered.


  • Open Access

    Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort

    by E. H. van der Geest, N. Ajmone Marsan, D. Laenens, P. J.M.R. Debonnaire, M. Claeys, F. Pinto, D. Brito, E. Donal, S. Droogmans, N. Van de Veire, et al.

    Background: Transthyretin cardiac amyloidosis (ATTR-CA) results from misfolded transthyretin protein deposition in the myocardium, causing restrictive cardiomyopathy, heart failure (HF), and conduction disorders. Conventional HF treatment in ATTR-CA is debated due to absent trial evidence. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort. Methods: A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divided based on guideline publication dates. Results: Patients were predominantly male (73.2%) with a median age of 78 years old. Prescription of diuretics (52.8%) and disease-modifying therapy (44.9%), mostly tafamidis, were common. BBs (43.7%) and ACEi/ARBs (41.2%) were prescribed more often in patients with higher NYHA class, elevated NT-proBNP, and more comorbidities. Blood pressure and heart rate were similar regardless of BB or ACEi/ARB use. BB prescription and combination therapy with BB and ACEi/ARB increased over time. Neither BB nor ACEi/ARB use significantly impacted mortality when analyzed in a multivariate Cox proportional hazard regression. Conclusions: BBs and ACEi/ARBs are more frequently used over time in particular in advanced-stage ATTR-CA patients and although BB and ACEi/ARB appear to be reasonably tolerated in the ones that were prescribed these drugs, survival was not significantly altered.

  • Open Access

    Surgical myectomy for hypertrophic cardiomyopathy: procedural volume and outcomes

    by Tijn J P Heeringa, Romy M J J Hegeman, Yvonne Koop, Sulayman el Mathari, Marieke Hoogewerf, Maaike M Roefs, Karin C Smits, Dorien Laenens, Giulia De Zan, Maarten J Cramer, et al.

    Background and Aims: Outcomes after surgical myectomy in hypertrophic obstructive cardiomyopathy (HOCM) patients have not been investigated in a multicentre registry with detailed clinical data. Hence, the objectives of this multicentre Dutch study are to describe the 30-day clinical outcomes after surgical myectomy, and to assess factors associated with increased 30-day complication rates. Methods: All HOCM patients (n = 335) who underwent surgery between 2012 and 2020 across 12 Dutch hospitals were analysed using data from the Netherlands Heart Registration. Multiple logistic regression analyses assessed factors associated with a higher 30-day complication rate. Results: Isolated surgical myectomy was performed in 22%, surgical myectomy with one concomitant procedure in 54%, and surgical myectomy with two or more concomitant procedures in 24%. Thirty-day complication rates concerned mortality (5%), ventricular septal defect (2%), stroke (3%), and surgical reoperation (2%). Mean resting left ventricular outflow tract (LVOT) gradient improved from 61 ± 30 mmHg to 13 ± 12 mmHg postoperatively, systolic anterior motion from 80% to 8%, and mitral regurgitation grade 3 or 4 from 31% to 6%. Low-volume hospital (<10 surgical myectomy procedures/year), female sex, and ≥2 concomitant procedures were significantly associated with increased 30-day complication rates. The adjusted 30-day complication rate was increased in low-volume hospitals (odds ratio 3.23 (95% confidence interval: 1.43–8.09); P = .007). Conclusions: Surgical myectomy with or without concomitant procedures effectively relieved LVOT obstruction in 93% of patients in this multicentre cohort. Female sex, ≥ 2 concomitant procedures, and low-volume hospitals were associated with higher 30-day complication rates. Although an inverse volume–complication relation was observed, this finding should be interpreted cautiously, and further investigation in larger sample size studies is warranted.


  • Open Access

    Incremental prognostic value of left atrial reservoir strain after ST-segment elevation myocardial infarction for the prediction of new-onset atrial fibrillation

    by Laima Caunite, Rinchyenkhand Myagmardorj, Xavier Galloo, Dorien Laenens, Jan Stassen, Takeru Nabeta, Idit Yedidya, Maria Chiara Meucci, Jurrien H. Kuneman, Inge J. van Den Hoogen, et al.

    New-onset atrial fibrillation (AF) affects up to 21% of ST-segment elevation myocardial infarction (STEMI) patients. The value of LA reservoir strain to predict new-onset AF in a STEMI population has not been thoroughly investigated. We aimed to explore the incremental value of LA reservoir strain for predicting new-onset AF post-STEMI. Data were analyzed retrospectively from an ongoing STEMI registry. LA reservoir strain < 23% on transthoracic echocardiography was used as threshold for impaired LA function. The endpoint was new-onset AF. In total, 1238 patients (age 60 ± 12 years, 75% male) were included. After a median follow-up of 23 months, 92 (7.4%) patients developed new-onset AF. A similar prevalence of LA volume index ≥ 34 ml/m2 was seen between post-STEMI patients who developed new-onset AF and those who did not. In contrast, impaired LA reservoir strain was 1.5 times more common in individuals who developed AF (72% versus 48%; p < 0.001). Cumulative, event-free survival rates at five years in patients with preserved versus impaired LA reservoir strain were 93% versus 84%, respectively (log-rank χ2 = 19.81; p < 0.001). On multivariate Cox regression analysis LA reservoir strain remained significantly associated with new-onset AF (HR 0.97 (95% CI: 0.94–0.99); p = 0.025). Addition of LA reservoir strain provided incremental prognostic value over baseline clinical and echocardiographic risk markers (χ2 56.93 vs. 59.98; p = 0.013). Impaired LA reservoir strain was 1.5 times more common in patients who experienced new-onset AF post-STEMI, and was of incremental value for predicting the development of AF after adjusting for clinical and echocardiographic risk factors. Graphical abstract Impaired LA reservoir strain was 1.5 times more common in patients who experienced new-onset AF post-STEMI, and was of incremental value for predicting the development of AF.


  • Open Access

    Association between echocardiography-derived haemodynamic force parameters and left ventricular reverse remodelling after cardiac resynchronization therapy

    by Dorien Laenens, Pieter van der Bijl, Xavier Galloo, Alessandro C Rossi, Giovanni Tonti, Johan H C Reiber, Gianni Pedrizzetti, Nina Ajmone Marsan, Jeroen J Bax

    Aims: Cardiac resynchronization therapy (CRT) may induce left ventricular (LV) reverse remodelling (=LV response) in patients with heart failure. Intraventricular pressure gradients can be quantified using echocardiography-derived haemodynamic forces (HDF). The aim was to evaluate the association between baseline HDF and LV response and to compare the change of HDF after CRT between LV responders and LV non-responders. Methods and results: The following HDF parameters were assessed: (i) apical–basal (AB) strength, (ii) lateral–septal strength, (iii) force vector angle, (iv) systolic AB impulse, (v) systolic force vector angle. LV response was defined as a reduction of LV end-systolic volume ≥ 15% at six months. One hundred ninety-six patients were included [64 ± 11 years, 122 (62%) men], 136 (69%) showed LV response. On multivariable logistic regression analysis, the force vector angle in the complete heart cycle [OR 1.083 (95% CI: 1.018, 1.153), P = 0.012] and the systolic force vector angle [OR 1.089 (95% CI: 1.021, 1.161), P = 0.009], both included in separate models, were independently associated with LV response. Six months after CRT, LV responders had greater AB strength, AB impulse, and higher force vector angles, while LV non-responders only showed improvement in the force vector angle in the complete heart cycle. Conclusion: The orientation of HDF at baseline is associated with LV response to CRT. Six months after CRT, the orientation of HDF improves in LV responders and LV non-responders, while the magnitude of AB HDF only improves in LV responders.


  • Open Access

    Evolution of Echocardiography-Derived Hemodynamic Force Parameters After Cardiac Resynchronization Therapy

    by Dorien Laenens, Pieter van der Bijl, Xavier Galloo, Alessandro C. Rossi, Giovanni Tonti, Johan H. Reiber, Gianni Pedrizzetti, Nina Ajmone Marsan, Jeroen J. Bax


  • Open Access

    Association Between Left Ventricular Apical-to-Basal Strain Ratio and Conduction Disorders after Aortic Valve Replacement

    by Dorien Laenens, Jan Stassen, Xavier Galloo, Rinchyenkhand Myagmardorj, Nina Ajmone Marsan, Jeroen J. Bax


  • Open Access

    The impact of atrial fibrillation on prognosis in aortic stenosis

    by Dorien Laenens, Jan Stassen, Xavier Galloo, See Hooi Ewe, Gurpreet K Singh, Mohammed R Ammanullah, Kensuke Hirasawa, Ching-Hui Sia, Steele C Butcher, Nicholas W S Chew, et al.

    Atrial fibrillation (AF) and aortic stenosis (AS) are both highly prevalent and often coexist. Various studies have focused on the prognostic value of AF in patients with AS, but rarely considered left ventricular (LV) diastolic function as a prognostic factor. To evaluate the prognostic impact of AF in patients with AS while correcting for LV diastolic function. Patients with first diagnosis of significant AS were selected and stratified according to history of AF. The endpoint was all-cause mortality. In total, 2849 patients with significant AS (mean age 72 ± 12 years, 54.8% men) were evaluated, and 686 (24.1%) had a history of AF. During a median follow-up of 60 (30–97) months, 1182 (41.5%) patients died. Ten-year mortality rate in patients with AF was 46.8% compared to 36.8% in patients with sinus rhythm (SR) (log-rank P < 0.001). On univariable (HR: 1.42; 95% CI: 1.25–1.62; P < 0.001) and multivariable Cox regression analysis (HR: 1.19; 95% CI: 1.02–1.38; P = 0.026), AF was independently associated with mortality. However, when correcting for indexed left atrial volume, E/e’ or both, AF was no longer independently associated with all-cause mortality. Patients with significant AS and AF have a reduced survival as compared to patients with SR. Nonetheless, when correcting for markers of LV diastolic function, AF was not independently associated with outcomes in patients with significant AS.